Chemotherapy Communication FDA Immunization 
Pharmafile
JANUARY 27, 2023
The FDA has revoked its approval of AstraZeneca’s Evusheld due to the fact that it is not effective against more than 90% of COVID-19 variants currently in circulation in the US. read more
Pharmaceutical Technology
MAY 31, 2023
In January 2021, the US Food and Drug Administration (FDA) granted SNIPR001 a fast track designation. Several CRISPR-based gene therapies are in development , with one for sickle cell disease and transfusion-dependent beta thalassemia (TDT), being examined by the FDA for an approval. Please check your email to download the Report.
Expert insights. Personalized for you.
52 
Let's personalize your content